Cara Therapeutics Inc (CARA)

$0.6716

-0.04

(-5.02%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Cara Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 6.93M → 3.00M (in $), with an average decrease of 34.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -28.03M → -32.33M (in $), with an average decrease of 15.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 132.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 338.2%

Performance

  • $0.66
    $0.72
    $0.67
    downward going graph

    1.3%

    Downside

    Day's Volatility :8.15%

    Upside

    6.94%

    downward going graph
  • $0.50
    $4.67
    $0.67
    downward going graph

    25.37%

    Downside

    52 Weeks Volatility :89.29%

    Upside

    85.65%

    downward going graph

Returns

PeriodCara Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
18.95%
1.7%
0.0%
6 Months
-45.4%
11.3%
0.0%
1 Year
-82.91%
5.4%
1.3%
3 Years
-97.47%
13.9%
-22.1%

Highlights

Market Capitalization
39.9M
Book Value
$1.05
Earnings Per Share (EPS)
-2.19
PEG Ratio
0.0
Wall Street Target Price
5.23
Profit Margin
0.0%
Operating Margin TTM
-1085.45%
Return On Assets TTM
-49.3%
Return On Equity TTM
-109.8%
Revenue TTM
21.0M
Revenue Per Share TTM
0.39
Quarterly Revenue Growth YOY
-7.9%
Gross Profit TTM
-56.1M
EBITDA
-121.2M
Diluted Eps TTM
-2.19
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.09
EPS Estimate Next Year
-1.02
EPS Estimate Current Quarter
-0.41
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Cara Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 678.74%

Current $0.67
Target $5.23

Company Financials

FY18Y/Y Change
Revenue
13.5M
↑ 1378.49%
Net Income
-74.0M
↑ 27.33%
Net Profit Margin
-549.51%
↑ 5830.84%
FY19Y/Y Change
Revenue
19.9M
↑ 47.64%
Net Income
-106.4M
↑ 43.72%
Net Profit Margin
-534.91%
↑ 14.6%
FY20Y/Y Change
Revenue
135.1M
↑ 579.28%
Net Income
8.4M
↓ 107.91%
Net Profit Margin
6.23%
↑ 541.14%
FY21Y/Y Change
Revenue
23.0M
↓ 82.95%
Net Income
-88.2M
↓ 1148.67%
Net Profit Margin
-382.98%
↓ 389.21%
FY22Y/Y Change
Revenue
41.9M
↑ 81.81%
Net Income
-83.4M
↓ 5.42%
Net Profit Margin
-199.23%
↑ 183.75%
FY23Y/Y Change
Revenue
21.0M
↓ 49.92%
Net Income
-118.5M
↑ 42.08%
Net Profit Margin
-565.21%
↓ 365.98%
Q3 FY22Q/Q Change
Revenue
10.8M
↓ 52.99%
Net Income
-22.5M
↑ 471.45%
Net Profit Margin
-208.22%
↓ 191.09%
Q4 FY22Q/Q Change
Revenue
3.3M
↓ 69.84%
Net Income
-29.4M
↑ 30.45%
Net Profit Margin
-900.67%
↓ 692.45%
Q1 FY23Q/Q Change
Revenue
6.2M
↑ 89.05%
Net Income
-25.7M
↓ 12.57%
Net Profit Margin
-416.55%
↑ 484.12%
Q2 FY23Q/Q Change
Revenue
6.9M
↑ 12.46%
Net Income
-31.5M
↑ 22.58%
Net Profit Margin
-454.05%
↓ 37.5%
Q3 FY23Q/Q Change
Revenue
4.9M
↓ 29.81%
Net Income
-28.0M
↓ 10.95%
Net Profit Margin
-576.08%
↓ 122.03%
Q4 FY23Q/Q Change
Revenue
3.0M
↓ 38.27%
Net Income
-32.3M
↑ 15.36%
Net Profit Margin
-1.1K%
↓ 500.38%
FY18Y/Y Change
Total Assets
190.8M
↑ 96.72%
Total Liabilities
57.2M
↑ 459.4%
FY19Y/Y Change
Total Assets
233.0M
↑ 22.08%
Total Liabilities
46.2M
↓ 19.14%
FY20Y/Y Change
Total Assets
271.2M
↑ 16.4%
Total Liabilities
22.2M
↓ 52.09%
FY21Y/Y Change
Total Assets
247.1M
↓ 8.89%
Total Liabilities
19.5M
↓ 11.83%
FY22Y/Y Change
Total Assets
182.2M
↓ 26.24%
Total Liabilities
23.5M
↑ 20.09%
FY23Y/Y Change
Total Assets
125.8M
↓ 30.94%
Total Liabilities
68.8M
↑ 193.12%
Q3 FY22Q/Q Change
Total Assets
213.5M
↓ 5.77%
Total Liabilities
28.7M
↑ 29.52%
Q4 FY22Q/Q Change
Total Assets
182.2M
↓ 14.65%
Total Liabilities
23.5M
↓ 18.23%
Q1 FY23Q/Q Change
Total Assets
153.3M
↓ 15.89%
Total Liabilities
16.7M
↓ 28.9%
Q2 FY23Q/Q Change
Total Assets
134.4M
↓ 12.32%
Total Liabilities
25.5M
↑ 52.64%
Q3 FY23Q/Q Change
Total Assets
115.3M
↓ 14.18%
Total Liabilities
29.7M
↑ 16.65%
Q4 FY23Q/Q Change
Total Assets
125.8M
↑ 9.11%
Total Liabilities
68.8M
↑ 131.54%
FY18Y/Y Change
Operating Cash Flow
-22.3M
↓ 59.32%
Investing Cash Flow
-82.8M
↑ 131.34%
Financing Cash Flow
110.8M
↑ 26.03%
FY19Y/Y Change
Operating Cash Flow
-109.2M
↑ 389.78%
Investing Cash Flow
-30.5M
↓ 63.15%
Financing Cash Flow
142.6M
↑ 28.69%
FY20Y/Y Change
Operating Cash Flow
-5.5M
↓ 94.98%
Investing Cash Flow
-20.3M
↓ 33.56%
Financing Cash Flow
39.1M
↓ 72.55%
FY21Y/Y Change
Operating Cash Flow
-60.1M
↑ 995.08%
Investing Cash Flow
-4.8M
↓ 76.57%
Financing Cash Flow
46.6M
↑ 19.08%
FY22Y/Y Change
Operating Cash Flow
-78.7M
↑ 31.03%
Investing Cash Flow
128.7M
↓ 2809.05%
Financing Cash Flow
311.0K
↓ 99.33%
Q3 FY22Q/Q Change
Operating Cash Flow
-25.2M
↑ 459.45%
Investing Cash Flow
21.2M
↓ 28.65%
Financing Cash Flow
104.0K
↓ 42.86%
Q4 FY22Q/Q Change
Operating Cash Flow
-23.5M
↓ 6.68%
Investing Cash Flow
44.4M
↑ 109.78%
Financing Cash Flow
22.0K
↓ 78.85%
Q1 FY23Q/Q Change
Operating Cash Flow
-34.6M
↑ 47.25%
Investing Cash Flow
17.7M
↓ 60.14%
Financing Cash Flow
560.0K
↑ 2445.45%
Q2 FY23Q/Q Change
Operating Cash Flow
-20.4M
↓ 40.94%
Investing Cash Flow
32.8M
↑ 85.24%
Financing Cash Flow
1.1M
↑ 99.29%
Q3 FY23Q/Q Change
Operating Cash Flow
-19.6M
↓ 3.91%
Investing Cash Flow
23.2M
↓ 29.41%
Financing Cash Flow
1.1M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Cara Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cara Therapeutics Inc
Cara Therapeutics Inc
-18.09%
-45.4%
-82.91%
-97.47%
-96.54%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cara Therapeutics Inc
Cara Therapeutics Inc
NA
NA
0.0
-1.09
-1.1
-0.49
NA
1.05
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cara Therapeutics Inc
Cara Therapeutics Inc
Buy
$39.9M
-96.54%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • BlackRock Inc

    6.50%

  • Vanguard Group Inc

    4.81%

  • Disciplined Growth Investors Inc

    3.32%

  • Chescapmanager LLC

    3.21%

  • Farallon Capital Management, L.L.C.

    2.85%

  • Jacobs Levy Equity Management, Inc.

    2.64%

Corporate Announcements

  • Cara Therapeutics Inc Earnings

    Cara Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Organization
Cara Therapeutics Inc
Employees
55
CEO
Mr. Christopher A. Posner
Industry
Health Technology

Discover More

FAQs